[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vagus-nerve-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vagus-nerve-stimulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,50,73,103,137,163,190,227,255,284,307,339,362,380,415],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639248","effects-of-transcutaneous-vagal-nerve-stimulation-on-post-surgical-return-to-consciousness-delirium-and-depression-100639248",false,"NCT07610655","Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression","tVNS","Inclusion Criteria:\n\n1. Aged \\> 18 years of age\n2. Patients undergoing lumbar surgery for degenerative disc disease or spinal stenosis involving two or more levels\n3. Montreal Cognitive Assessment (MoCA) score ≥ 18 - accept mild\n4. Ability to use a keyboard\n5. Able to understand and communicate in English\n6. Be able to consent independently\n7. Women of child-bearing age must be comfortable confirming a negative pregnancy prior to participating in the study.\n8. Must not be involved in any other research intervention study testing neurobehavioral functioning\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years of age\n2. History of vagotomy (cutting the vagus nerve)\n3. History of bradycardia, heart block, prolonged QT syndrome, brugada syndrome, heart failure with ejection fraction less than 35% and\u002For New York Heart Association symptoms\n4. MoCA \\\u003C 18\n5. History of seizure disorder or intracranial hemorrhage\n6. Patients with carotid stenosis\n7. Patients with aneurysms\n8. Other neurological diagnoses or a diagnosis of severe psychiatric disorder (e.g., psychosis) or a reported childhood learning disability\n9. Pregnancy, breastfeeding\n10. Active addiction history\n11. ECG adhesive allergy\n12. Severe aphasia, preventing subject from understanding the protocol and giving written consent\n13. Patients will be excluded postoperatively if there is neck swelling at the proposed site of left tcVNS.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will examine whether noninvasive, transcutaneous vagal nerve stimulation (tcVNS) can help restore consciousness in patients in the operating room and the Post Anesthesia Care Unit (PACU). The study will also investigate if tcVNS can expedite discharge from the PACU and examine whether tcVNS administerd in the PACU helps reduce delirium and depression after surgery. The study will also evaluate whether tcVNS speeds cognitive recovery from emergence of anesthesia and surgery.",[26,27,28,29],"Post Operative Delirium","Cognitive Impairment","Vagus Nerve Stimulation","Depression",[31,32,33,28,34,35,29,36],"Anesthesia Care","Post Anesthesia Care","Post Surgical Care","Delirium","Cognitive Imparment","Hospital Length of Stay","RECRUITING","2026-05-26",{"date":40,"type":41},"2026-05-28","ACTUAL",{"date":43,"type":41},"2026-04-23",{"date":45,"type":20},"2029-05-31",{"name":47,"class":48},"Northwestern University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":49},"100628110","how-does-vagus-nerve-stimulation-affect-blood-glucose-food-and-movement-cravings-100628110","NCT07457372","How Does Vagus Nerve Stimulation Affect Blood Glucose, Food, and Movement Cravings?","Inclusion Criteria:\n\n* Participants must be between the ages of 18 and 35 as we are focused on recruiting undergraduate and graduate students.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have epilepsy, clinically significant tachycardia or arrhythmia, diabetes (Type 1 or Type 2) or another metabolic disease, current pregnancy, any implanted electronic medical device (for example, pacemaker or defibrillator), or a known skin allergy to adhesives that would prevent CGM placement. Participants will also be excluded if they have a history of major depressive disorder if taVNS could reasonably be expected to alter mood symptoms",true,"35 Years",{"count":59,"type":20},8,[23],"The purpose of this study is to determine the feasibility of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to examine physiological and psychological responses in a college-aged healthy population",[28],"NOT_YET_RECRUITING","2026-05-18",{"date":66,"type":41},"2026-05-20",{"date":68,"type":20},"2026-07-01",{"date":70,"type":20},"2028-05-01",{"name":72,"class":48},"University of Minnesota",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":49},"100505829","phase-1-the-enhance-study-tavns-and-psilocybin-100505829","NCT05866471","The ENHANCE Study: taVNS and Psilocybin","Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin","ENHANCE","Inclusion Criteria:\n\n* English speaking\n* Ability\u002Fwillingness to complete all study activities\n* Modest reduction in emotional well-being\n* Medically healthy (does not meet criteria for an exclusionary medical condition)\n* Blood pressure and heart rate within established ranges at screening\n* Use of acceptable contraceptive methods (sexually active males and women of childbearing potential)\n\nExclusion Criteria:\n\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Current or clinically significant psychiatric disorder that, in the investigator's judgment, would interfere with participation or increase risk\n* Current use of drugs or medications, prescribed or otherwise, that may interact with psilocybin\n* Use of investigational drugs, biologics, or devices within 30 days of enrollment\n* Use of psychedelic or related agents within three months of Dosing Day\n* Clinically significant electrocardiogram (ECG)\n* Vitals outside acceptable range\n* Pregnancy and currently breastfeeding\n* Unwillingness to go without tobacco products for 12 hours or more\n* Inability to undergo fMRI scanning\n* Recent ear trauma, hearing loss (if clinically significant), or deafness\n* Family history of a psychotic disorder in a first degree relative","70 Years",{"count":83,"type":20},108,[85],"PHASE1","This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS or no VNS.",[88,89,28],"Healthy","Psychedelic Experiences",[91,92,28,93],"Psilocybin","Psychedelics","Healthy Volunteer","2026-03-31",{"date":96,"type":41},"2026-04-03",{"date":98,"type":41},"2025-01-27",{"date":100,"type":20},"2028-01",{"name":102,"class":48},"University of Wisconsin, Madison",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":49},"100614033","frequency-dependent-effects-of-auricular-vagus-nerve-stimulation-on-autonomic-and-cardiovascular-parameters-100614033","NCT07274332","Frequency-Dependent Effects of Auricular Vagus Nerve Stimulation on Autonomic and Cardiovascular Parameters","Acute Effects of Different Frequencies of Auricular Vagus Nerve Stimulation on HRV, Blood Pressure, and Respiratory Rate: A Sham-Controlled, Randomized, Crossover Dose-Response Study","AVNS-DRC","Inclusion Criteria:\n\n* 18-30 years\n* Healthy (self-reported)\n* No cardiovascular, neurological, metabolic or psychiatric disorders\n* No regular medication affecting autonomic function\n* Non-smoker\n* BMI 18-29.9\n\nExclusion Criteria:\n\n* Pregnancy\n* Cardiac arrhythmia\n* Hypertension or hypotension\n* Chronic respiratory disorders\n* Active infection\n* Metal implants in cervical area\n* Epilepsy\n* Syncope history\n* Prior vagus stimulation experience","30 Years",{"count":113,"type":20},36,[23],"This randomized, sham-controlled, crossover study investigates the acute autonomic effects of transcutaneous cervical vagus nerve stimulation (tcVNS) applied at five different frequencies (0 Hz\u002Fsham, 10 Hz, 25 Hz, 50 Hz, 100 Hz) in healthy adults. The primary objective is to determine how stimulation frequency modulates heart rate variability (HRV), blood pressure, and respiratory rate. The study aims to establish a frequency-specific dose-response model using validated physiological measurements.",[28,117,118,119,120,121],"Autonomic Nervous System","Heart Rate","Blood Pressure","Respiration","Healthy Volunteers",[123,124,125,126,127],"Transcutaneous Cervical Vagus Nerve Stimulation","Neuromodulation","Non-invasive Vagus Stimulation","Parasympathetic Activation","Heart Rate Variability","2025-11-27",{"date":130,"type":41},"2025-12-10",{"date":132,"type":20},"2025-12-22",{"date":134,"type":20},"2026-03-15",{"name":136,"class":48},"SEFA HAKTAN HATIK",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100612630","effects-of-transcutaneous-auricular-vagus-nerve-stimulation-on-cognitive-performance-and-sex-differences-100612630","NCT07256080","Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Cognitive Performance and Sex Differences","A Sham-Controlled Cross-Over Study Examining the Effects of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Cognitive Performance and Gender Differences in Healthy Adults","Inclusion Criteria:\n\n* Healthy young adults aged 18-30 years\n* Ability to provide informed consent\n* Right-handed participants (to reduce variability in cognitive performance)\n* Normal or corrected-to-normal vision and hearing\n* Female participants tested during the follicular phase of the menstrual cycle (days 5-10) to minimize hormonal effects on cognition and vagal tone\n\nExclusion Criteria:\n\n* History of neurological or psychiatric disorders\n* Cardiovascular disease\n* Use of psychoactive medications\n* Substance dependence, including alcohol, illicit drugs, or nicotine\n* Pregnancy or breastfeeding\n* Skin conditions or ear anomalies that interfere with electrode placement\n* Metal implants in the head or neck region\n* History of epilepsy or migraine",{"count":145,"type":20},60,[23],"This study investigates the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on cognitive performance in healthy adults. The study uses a sham-controlled, cross-over design in which each participant receives both active taVNS and sham stimulation in separate sessions. Each participant completes both conditions (active and sham) in a randomized order using a crossover design. Cognitive performance will be assessed before and after each session using standardized tests. The study also explores whether males and females respond differently to taVNS, in order to identify potential sex-related differences in cognitive outcomes.",[149,150,151,28,152,153,124,154],"Cognitive Assessment","Cognition","taVNS","Executive Functions","Healthy Participants","Sex Differences",{"date":156,"type":41},"2025-12-01",{"date":158,"type":20},"2025-12",{"date":160,"type":20},"2026-05",{"name":162,"class":48},"Bahçeşehir University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":49},"100602088","respiratory-gated-transcutaneous-auricular-vagus-nerve-stimulation-for-improving-apathy-in-parkinsons-disease-100602088","NCT07118956","Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease","Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease: A Randomized, Double-blind, Sham-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for idiopathic Parkinson's disease (based on the MDS Clinical Diagnostic Criteria for Parkinson's Disease (2015 version)).\n2. Patients with Apathy Motivation Index (AMI) score \\>1.7.\n3. All PD patients must be on stable, standardized medication regimens with no adjustments to medications for at least 1 month prior to the study and throughout the study period.\n4. Demonstrate good compliance and adherence, capable of completing behavioral tests and taVNS therapy.\n5. Mini-Mental State Examination (MMSE) score ≥22.\n6. Meet safety criteria for MRI screening.\n\nExclusion Criteria:\n\n1. Prior brain MRI\u002FCT showing focal brain lesions or severe white matter disease (Fazekas grade 3 or higher).\n2. Secondary parkinsonism (e.g., vascular parkinsonism, drug-induced parkinsonism).\n3. History of severe traumatic brain injury, neurosurgery, or deep brain stimulation (DBS) therapy.\n4. Personal history of epilepsy, unexplained loss of consciousness, or current use of anticonvulsant medications for seizure control.\n5. Diagnosis of neuropsychiatric disorders other than Parkinson's disease.\n6. Current use of non-steroidal anti-inflammatory drugs (NSAIDs) or Non-benzodiazepine GABA receptor agonist drug or anticholinergics or corticosteroids, or history of substance abuse or drug addiction.\n7. Participation in any clinical trial within the past 3 months.\n8. Severe systemic comorbidities (e.g., hepatic\u002Frenal failure, arrhythmias, organic heart disease).\n9. Pregnant\u002Flactating women or subjects (including males) planning pregnancy within 6 months.\n10. Contraindications to taVNS, such as cardiac pacemakers, post-DBS surgery, or auricular pathologies (e.g., tympanic membrane perforation).","40 Years","90 Years",{"count":145,"type":20},[23],"The goal of this clinical trial is to learn whether 100HZ respiratory-gated vagus nerve stimulation (RAVANS) can improve the non-motor symptoms in people with Parkinson's disease (PD). It will also learn the safety of 100HZ RAVANS. The main questions it aims to answer are:\n\nCan 100HZ RAVANS improve apathy in people with PD? Did the participants have any side effects or safety issues when undergoing 100HZ RAVANS? Researchers compared 100HZ RAVANS with sham stimulation (low-dose stimulation of the same site and treatment parameters) to see if 100HZ RAVANS could improve non-motor symptoms in patients with PD.\n\nParticipants will:\n\nReceive 100HZ RAVANS or sham stimulation for 2 weeks. Neuropsychological assessment, imaging and biological sample collection were conducted before and after the entire cycle.",[176,177,178,28],"Parkinson Disease","Apathy","Non-motor Symptoms",[176,177,180,181],"Non-motor symptoms","Transcutaneous Auricular Vagus Nerve Stimulation","2025-11-17",{"date":184,"type":41},"2025-11-19",{"date":186,"type":41},"2025-05-01",{"date":70,"type":20},{"name":189,"class":48},"Anhui Medical University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":49},"100515496","auricular-vagus-stimulation-and-stemi-100515496","NCT05992259","Auricular Vagus Stimulation and STEMI","Auricular Vagus Stimulation and ST-Segment Elevation Myocardial Infarction","Inclusion Criteria:\n\n* patients with STEMI who have signed an informed voluntary consent to participate in the study;\n* primary myocardial infarction;\n* treatment in the first 12 hours from the onset of pain syndrome;\n* primary PCI.\n\nExclusion Criteria:\n\n* acute heart failure III-IV;\n* bradyarrhythmias;\n* atrial fibrillation\u002Fflutter at the time of switching on;\n* Thrombolytic therapy at the prehospital stage;\n* a history of myocardial infarction;\n* PCI\u002Fcoronary artery bypass grafting (CABG) in the anamnesis.","75 Years",{"count":199,"type":20},300,[23],"At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficiency of providing medical care to patients with acute coronary syndrome (ACS), there remains a high mortality and disability of this group of patients. In this regard, the search for new drug and non-drug strategies for the treatment of patients with ACS is actively continuing. Over the past decade, it has been shown that transcutaneous vagus nerve stimulation (TENS) has a cardioprotective effect both in chronic heart failure and in coronary heart disease, improves cardiac function, prevents reperfusion injury, weakens myocardial remodeling, increases the effectiveness of defibrillation and reduces the size of a heart attack. One of the methods of noninvasive stimulation of the afferent fibers of the vagus nerve is percutaneous electrical stimulation of the auricular branch of the vagus nerve. However, further studies are needed to determine whether stimulation of the tragus can improve the long-term clinical outcome in this cohort of patients.",[28,203,204],"Acute Coronary Syndrome","Ischemia Reperfusion Injury",[206,207,208,209,210,211,212,213,214,215,216],"auricular stimulation","auricular vagus nerve stimulation","transcutaneous vagus nerve stimulation (TENS)","vagus nerve stimulation (VNS)","acute coronary syndrome","myocardial ischemia reperfusion injury","ST-segment elevation myocardial infarction","coronary heart disease","acute myocardial infarction","mortality","atrial fibrillation","2025-06-17",{"date":219,"type":41},"2025-06-18",{"date":221,"type":41},"2022-09-01",{"date":223,"type":20},"2026-12-01",{"name":225,"class":226},"Bakulev Scientific Center of Cardiovascular Surgery","OTHER_GOV",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":253,"locationsCount":254},"100491531","auricular-vagus-stimulation-and-heart-rate-variability-100491531","NCT05680337","Auricular Vagus Stimulation and Heart Rate Variability","Transcutaneous Electrical Auricular Vagus Stimulation and Heart Rate Variability","Inclusion Criteria:\n\n* Sinus rhythm at the time of registration\n\nExclusion Criteria:\n\n* Frequent ventricular \u002F supraventricular extrasystole, 2d\u002F3d degree AV Block\n* Taking glucocorticosteroids in the last 1 month\n* Taking any antiarrhythmics, except beta blockers\n* Severe chronic renal or liver pathology",{"count":235,"type":20},600,[23],"Transcutaneous electrical stimulation of the auricular vagus nerve (TENS) is a promising method of neuromodulation of the autonomic nervous system in patients with various pathologies. The use of this method requires the determination of a reliable biomarker of successful activation of the vagus nerve using TENS. Currently, most studies focus on the assessment of heart rate variability (HRV) as a marker of the functioning of the autonomic nervous system.\n\nDespite the physiological justification of HRV as a biomarker for TENS, the data on the effects of TENS on HRV are ambiguous. In some studies, a significant decrease in the ratio of spectral characteristics (LF\u002FHF) in active TENS was found in comparison with fictitious stimulation (sham), which indicated an increase in the parasympathetic component of HRV. However, other studies have not revealed an increase in HRV.",[28,127],[206,207,240,208,209,241,242,243,244,245,246,247,248],"heart rate","heart rate variability","power of high-frequency oscillations (HF)","power of low-frequency oscillations (LF)","power of very low frequency oscillations (VLF)","power of ultra-low frequency oscillations (ULF)","LF\u002FHF","index centralization (IC)","index of vegetative balance (IVB)",{"date":219,"type":41},{"date":251,"type":41},"2022-12-01",{"date":68,"type":20},{"name":225,"class":226},3,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":266,"conditions":267,"keywords":271,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":49},"100589707","transcutaneous-auricular-vagus-nerve-stimulation-and-quality-of-recovery-after-major-noncardiac-surgery-100589707","NCT06957912","Transcutaneous Auricular Vagus Nerve Stimulation and Quality of Recovery After Major Noncardiac Surgery","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Quality of Recovery After Major Noncardiac Surgery: A Randomized Trial.","Inclusion Criteria:\n\n1. Aged ≥18 years but \\\u003C85 years.\n2. Scheduled for elective or limited-time noncardiac surgery with expected duration ≥2 hours.\n\nExclusion Criteria:\n\n1. Lesions or infections of the auricle skin.\n2. Recent or long-term use of cholinergic or anticholinergic medications.\n3. Neurosurgery.\n4. Expected mechanical ventilation with intubation for ≥1 day after surgery.\n5. Diagnosed schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery.\n6. Preoperative left ventricular ejection fraction (LVEF) \\\u003C30%, or those with sick sinus syndrome, sinus bradycardia (heart rate \\\u003C50 beats per minute), atrioventricular block of grade II or above, or implanted pacemaker.\n7. Inability to communicate due to coma, severe dementia, or language barrier before surgery, or unable to cooperate with intervention.\n8. American Society of Anesthesiologists physical status grade \\>IV, or estimated survival \\\u003C24 hours.","85 Years",{"count":264,"type":20},320,[23],"Transcutaneous auricular vagus nerve stimulation (taVNS) is a novel non-invasive neuromodulation technique. Existing evidence suggested that taVNS improves pain management, sleep quality, inflammatory responses, and gastrointestinal recovery after surgery. This study is designed to test the hypothesis that perioperative use of taVNS may improve quality of recovery in patients after major noncardiac surgery.",[28,268,269,270],"Transcutaneous Electric Nerve Stimulation","Noncardiac Surgery","Quality of Recovery",[272,273,274],"Transcutaneous auricular vagus nerve stimulation","Noncardiac surgery","Quality of recovery","2025-06-02",{"date":277,"type":41},"2025-06-03",{"date":279,"type":41},"2025-05-13",{"date":281,"type":20},"2026-09",{"name":283,"class":48},"Peking University First Hospital",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":49},"100548444","transcutaneous-auricular-vagus-nerve-stimulation-prevents-postoperative-delirium-in-elderly-patients-100548444","NCT06421077","Transcutaneous Auricular Vagus Nerve Stimulation Prevents Postoperative Delirium in Elderly Patients","Transcutaneous Auricular Vagus Nerve Stimulation （taVNS）Prevents Postoperative Delirium in Elderly Patients: a Randomized Controlled Study","Vnstar","Inclusion Criteria:\n\n* Age≥65 years\n* Expected operation time≥ 2 hours\n* Postoperative hospital stay≥ 4 days\n* Sign the informed consent form\n\nExclusion Criteria:\n\n* Neurosurgery or cardiac surgery\n* Emergency surgery within 6 hours of admission\n* End-stage disease with an expected survival of \\\u003C 3 months\n* Preoperative severe cognitive dysfunction affected perioperative cognitive function assessment\n* Severe sinus bradycardia, AVB of degree II and above, pacemaker placement","65 Years",{"count":294,"type":20},1776,[23],"According to the 3D-CAM scale, evaluate the incidence of Postoperative Delirium within 5 days after surgery in elderly patients receiving taVNS.The results are expected to provide evidence of the safety and efficacy of perioperative prophylactic use of taVNS in the clinical application of improving postoperative brain health in elderly patients, as well as theoretical and practical basis for subsequent studies or clinical applications.",[28],"2025-04-21",{"date":300,"type":41},"2025-04-25",{"date":302,"type":41},"2024-06-20",{"date":304,"type":20},"2025-12-31",{"name":306,"class":48},"Beijing Tiantan Hospital",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":314,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":21,"phases":318,"briefSummary":319,"conditions":320,"keywords":325,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100584686","rehabilitation-paired-with-vns-for-motor-function-recovery-100584686","NCT06892574","Rehabilitation Paired with VNS for Motor Function Recovery","A Trial of Rehabilitation Paired with VNS for Motor Function Recovery in Post-ICH Patients (Recovery Study)","Inclusion Criteria:\n\n* Age ≥22 years and \\\u003C80 years, all gender is acceptable.\n* History of unilateral supratentorial intracerebral hemorrhage ≥ 6 months but \\\u003C 5 years.\n* Upper Extremity motor section of the Fugl-Meyer Assessment score ≥20 and ≤50.\n* Right- or left-sided weakness of upper extremity.\n* Ability to communicate, understand, and give appropriate consent. Subjects can follow trial commands.\n* Subjects have good compliance and can complete the visits after surgery.\n\nExclusion Criteria:\n\n* History of ischemic stroke.\n* Cerebral hemorrhage resulting from tumors, trauma, aneurysms, or hemorrhagic transformation of ischemic stroke.\n* Presence of ongoing dysphagia or aspiration difficulties.\n* Prior injury to vagus nerve, either bilateral or unilateral.\n* Subject receiving medication that may significantly interfere with actions of VNS on neurotransmitter systems at study entry, clinic rehabilitation follow-up timepoint, or home rehabilitation follow-up timepoint, such as centrally acting cholinoceptor blockers, centrally acting adrenoceptor blockers, norepinephrine re-uptake inhibitors, etc.\n* Botox injections within 4 weeks prior to enrollment through the unmasking follow-up timepoint (Visit 6).\n* Severe spasticity of the upper extremity (Modified Ashworth ≥ 3).\n* Significant sensory loss of the upper extremity (Upper Extremity sensory section of the Fugl-Meyer Assessment score \\\u003C 6).\n* Current requirement, or likely future requirement, of diathermy.\n* Current use of any other stimulation device, such as a pacemaker or other neurostimulator.\n* Pregnancy or plans to become pregnant or to breastfeed during the study period.\n* Participated in any other clinical trials within the preceding 3 months.\n* Not considered to be applicable by the investigator.","22 Years","79 Years",{"count":317,"type":20},10,[23],"The goal of this clinical trial is to investigate the efficacy and safety of vagus nerve stimulation (VNS) combined with rehabilitation in improving upper extremity motor function after spontaneous intracerebral hemorrhage (ICH).\n\nResearchers will evaluate the efficacy and safety of VNS by comparing the improvements of arm motor function post-ICH in the active VNS combined rehabilitation group with that in the sham VNS combined rehabilitation group (actual intensity 0 mA).\n\nParticipants in this study will undergo a surgical procedure to implant the VNS system and will subsequently recieve a 6 weeks in-clinic therapy, followed by an additional 6 weeks home exercise. During the final 6 weeks, participants will either recieve in-clinic therapy or maintain their home exercise, depending on their assigned group.",[321,322,323,324,28],"Spontaneous Intracerebral Hemorrhage","Motor Function","Upper Extremity Injury","Rehabilitation",[326,327,328,28,124,329,324],"Stroke","Hemorrhagic Stroke","Upper Extremity Paresis","Randomized Controlled Trial","2025-03-23",{"date":332,"type":41},"2025-03-26",{"date":334,"type":20},"2025-04-01",{"date":336,"type":20},"2027-12-30",{"name":338,"class":48},"First Affiliated Hospital of Fujian Medical University",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":360,"locationsCount":49},"100579272","effect-of-vagus-nerve-stimulation-via-the-outer-ear-on-motor-and-cognitive-deficits-after-ischemic-stroke-100579272","NCT06822140","Effect of Vagus Nerve Stimulation Via the Outer Ear on Motor and Cognitive Deficits After Ischemic Stroke","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Motor and Cognitive Deficits After Ischemic Stroke","EVAMOS","Inclusion Criteria:\n\n* Onset of stroke ≥15 days and ≤30 days after randomization\n* Ischemic stroke in the anterior cerebral circulation detected by MR imaging or computer tomography\n* National Institutes of Health Stroke Scale (NIHSS) score ≥3 points\n* Montreal Cognitive Assessment (MoCA) score ≤ 26 points\n* First ever stroke\n* Right-handed\n* Ability to participate in a standardized rehabilitation therapy\n* Written informed consent signed by the subject or next kin\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant and breastfeeding women\n* Severe concomitant neurological (brain tumor, encephalitis, Parkinson disease, epilepsy prior to stroke onset) or mental disorders (psychiatric conditions such as schizophrenia, uncontrolled depression or bipolar disorder before stroke onset)\n* Severe aphasia (i.e. unable to follow two-stage-commands)\n* Pre-existing hemiparesis\n* Documented history of dementia before index stroke\n* Primary intracranial hematoma or subarachnoid hemorrhage\n* Active implantable medical device (e.g., pacemaker, deep brain stimulator, cochlear implants, cerebral shunts)\n* Metal cervical spine hardware or metallic implant near the stimulation site\n* Modified Rankin scale (mRS) ≥ 2 prior to stroke onset\n* Low heart rate (\\\u003C 60 bpm)\n* Severe vision and hearing problems\n* Alcohol and drug abuse\n* Active post-stroke delirium, unable to cooperate\n* Type 1 and 2 diabetes mellitus\n* Sore and diseased skin of the auricle\n* Patients receiving any therapy (medication or otherwise) at study entry that would interfere with VNS",{"count":348,"type":20},144,[23],"The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to treat motor and neurocognitive deficits after ischemic stroke when applied within 30 days after onset of stroke.\n\nThe main questions it aims to answer are:\n\n* Does tVNS improve motor deficits measured by the Fugl-Mayer assessment after ischemic stroke?\n* Does tVNS ameliorate stroke-related cognitive impairment? Researchers will compare tVNS to a placebo (sham stimulation, i.e. an electrode is fixed on the ear without applying electrical impulses ) to see if tVNS works to treat motor and cognitive deficits after stroke .\n\nParticipants will:\n\n* Receive tVNS or sham stimulation for 30 minutes 5 days a week during 5 weeks after ischemic stroke\n* Receive smotor and cognitive training during the tVNS or sham stimulation\n* Will take part on a standardized stroke rehabilitation program during the 5 weeks in a rehabilitation clinic.",[352,353,27,28],"Ischemic Stroke","Motor Deficits","2025-02-16",{"date":356,"type":41},"2025-02-19",{"date":334,"type":20},{"date":359,"type":20},"2028-04-30",{"name":361,"class":48},"Rheinburg-Klinik",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":292,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":378,"leadSponsor":379,"locationsCount":49},"100548442","transauricular-vagus-nerve-stimulation-improves-postoperative-sleep-disorders-in-elderly-patients-100548442","NCT06421051","Transauricular Vagus Nerve Stimulation Improves Postoperative Sleep Disorders in Elderly Patients.","Transauricular Vagus Nerve Stimulation (taVNS) Improves Postoperative Sleep Disorders in Elderly Patients:a Randomized Controlled Study.","Vnstep","Inclusion Criteria:\n\n* Patients undergoing non-craniocerebral surgery under elective general anesthesia\n* Age ≥65 years old\n* American society of Aneshesiologists Grade I to III\n* Sign informed consent\n\nExclusion Criteria:\n\n* Patients who are expected to retain tracheal intubation after surgery\n* Disturbance of consciousness, mental disorder, inability to cooperate\n* Expected survival \\\u003C 3 months\n* The estimated operation time is \\\u003C 2 hours\n* The expected postoperative hospital stay is \\\u003C 5 days",{"count":371,"type":20},164,[23],"Postoperative sleep disorder is one of the common complications after general anesthesia. Compared to patients of various ages, elderly patients have a much higher incidence of postoperative sleep disturbance. Postoperative sleep disorders can have many adverse effects, including cognitive impairment, altered pain perception, and emotional disorders, which are not conducive to the long-term prognosis of elderly patients. Enhancing postoperative sleep quality in older patients has become a significant public health concern in the current day due to its direct relationship to both maximizing surgical outcomes and enhancing physical health. This study intends to conduct a prospective, randomized controlled, triple-blind clinical trial on use of transauricular vagal nerve stimulation to improve sleep disorders in elderly patients after general anesthesia surgery, aiming to investigate the efficacy of transauricular vagal nerve stimulation in postoperative sleep disorders in elderly patients.",[28],"2025-01-24",{"date":98,"type":41},{"date":302,"type":41},{"date":304,"type":20},{"name":306,"class":48},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":21,"phases":390,"briefSummary":391,"conditions":392,"keywords":400,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":4},"100471348","efficacy-of-transcutaneous-vagus-nerve-stimulation-paired-with-tailor-made-notched-music-therapy-versus-tailor-made-notched-music-training-for-chronic-subjective-tinnitus-100471348","NCT05417711","Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus","Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with tinnitus as the main complaint: the patients subjectively feel the sound in the ear or deep part of the head without internal or external sound stimulation, and therefore seek medical treatment\n* Chronic (≥ 6 months) and tonal tinnitus\n* Age 18-60\n* Tinnitus frequency is 125-8000 Hz\n* Hearing threshold at each frequency shall not exceed 70 dB HL\n\nExclusion Criteria:\n\n* Patients with conductive deafness, history of middle ear surgery, pulsatile tinnitus caused by vascular distortion and tinnitus caused by Meniere disease\n* History of head trauma, central nervous system diseases, mental diseases and drug abuse","60 Years",{"count":389,"type":20},388,[23],"This clinical study is a prospective, multicenter, randomized, controlled, double-blind clinical study. Sun Yat Sen Memorial Hospital of Sun Yat sen University was the central unit, and Nanjing First Hospital, Sun Yat Sen people's Hospital, Guanfzhou Panyu central Hospital and Zhuhai integrated traditional Chinese and Western medicine hospital were the cooperative units. In this study, 388 patients with chronic subjective tinnitus were recruited. In view of chronic subjective tinnitus, a common ear disease, the study gave the patients three months of treatment with transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy or tailor-made notched music training alone. By comparing the changes of subjective scale scores related to tinnitus before and after treatment in patients receiving two different therapies, such as THI, VAS, BAI, BDI, PSQI, to evaluate the efficacy of the two therapies, so as to judge whether transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy is better than tailor-made notched music training alone. In addition, the study will continue to follow up the patients after the treatment for one year to observe the difference in the long-term sustained efficacy of the two therapies. This clinical study will also evaluate the two therapies from the perspective of compliance and safety, and explore the factors that affect the efficacy of the two therapies.",[393,28,394,395,396,397,398,399],"Tinnitus, Subjective","Music Therapy","Double-Blind Method","Female","Male","Humans","Treatment Outcome",[401,402,403,404,405],"Chronic subjective tinnitus","Tailor-made notched music training","Vagus nerve stimulation","Electroencephalogram","Clinical trial","2023-11-22",{"date":408,"type":41},"2023-11-27",{"date":410,"type":20},"2023-11-23",{"date":412,"type":20},"2026-09-01",{"name":414,"class":48},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":21,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":49},"100525454","safety-and-efficacy-study-of-implantable-neuromodulation-for-poststroke-hemiplegia-100525454","NCT06121947","Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia","Comparative Study of the Efficacy and Safety of Deep Brain Stimulation Versus Vagal Stimulation for Post-stroke Hemiplegia: Study Protocol for a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meet WHO or international diagnostic criteria for stroke disease;\n2. The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1 year, and participate in 2 evaluations (screening and baseline) before enrollment.\n3. Diagnosed by professional physicians combined with brain CT or magnetic resonance imaging and other imaging techniques;\n4. Between the ages of 18 and 80, male or female\n5. The responsible lesion in the unilateral white matter area indicated by cranial CT or MRI\n6. Relevant sequelae such as limb dysfunction after stroke, accompanied by unilateral limb motor dysfunction, proved to be right-handed by standardized examination.\n7. National Institutes of Health Stroke Scale (NIHSS) score from 2 to 20, grades paralyzed muscle strength, between grades 1 and 4, WISCI II, grade \\>2 (0-20 items): Assisted by one or more persons, able to walk at least 10 m, and less responsive to conventional rehabilitation prior to inclusion.\n8. Perfect clinical data\n9. Stable medical and physical condition with adequate nursing support and appropriate medical care in the patient's home community.\n10. The patient himself or voluntarily signs the informed consent and is willing to cooperate with relevant treatmen\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE) assessment for dementia indicated, suffering from mental disturbance and unable to cooperate with examination or treatment.\n2. Motor and sensory disturbances are not induced by stroke, nor by previous ischemic stroke, but stroke induced by trauma, brain tumor, etc.\n3. Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or hematopoietic system diseases.\n4. History of cognitive impairment, mental disorder, drug abuse, drug allergy, and alcoholism.\n5. Infection or rupture of the skin on the forearm or leg.\n6. Possess a pacemaker, metal stent, plate, or implant susceptible to electrical impulses in the body (pacemaker or defibrillator, baclofen pump, deep brain stimulator, Ventricular shunts, shrapnel, etc.).\n7. Pregnant or breast-feeding or have a recent birth plan.\n8. IS CLASSROUS.\n9. Congenital or acquired abnormalities of lower extremities (affecting joints and bones).\n10. Registration of investigators, their family members, employees, and other dependents.\n11. Severe joint contractures cause loss or limitation of lower limb activities.\n12. Blood system diseases with increased risk of bleeding during surgical intervention.\n13. Participate in another study drug study within 30 days before and during this study.\n14. Unable to complete the basic process, or difficult to maintain compliance and follow-up","80 Years",{"count":424,"type":20},98,[23],"Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus nerve stimulation (VNS) can improve the motor function of patients, but there is no comparative study between them. Objectives: This study compares the efficacy and safety of DBS and VNS in the recovery of motor function in patients with post-stroke hemiplegia, determining the best treatment for patients with post-stroke hemiplegia, and providing high-level clinical evidence for patients and clinicians to choose from. Methods\u002FDesign: This is a randomized, double-blind, sham-controlled, cross-controlled pilot study. A total of 98 patients with post-stroke hemiplegia are assigned to receive DBS or VNS. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Discussion: We propose a study design and rationale to compare the efficacy and safety of DBS and VNS in patients with post-stroke hemiplegia to provide evidence and reference for implantable neuromodulation in the treatment of post-stroke dysfunction, and to compare the therapeutic effects of DBS and VNS to provide evidence for patient and clinical diagnosis and treatment choices. Study limitations are related to the small sample size and short study period.",[428,429,28,430,326,431],"Stroke Sequelae","Deep Brain Stimulation","Motor Recovery","Hemiplegia","2023-11-02",{"date":434,"type":41},"2023-11-08",{"date":436,"type":20},"2023-11-10",{"date":438,"type":20},"2030-10-30",{"name":440,"class":48},"Chinese PLA General Hospital"]